« Back
Home /
Pelitinib

Pelitinib

Item no.	M1904-200mg
Manufacturer	AbMole
CASRN	257933-82-7
Amount	200mg
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Breast Cancer
Type	Inhibitors
Specific against	other
Purity	>98.0%
Citations	Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways. Kim H, et al . J Korean Med Sci. 2011 Dec,26(12):1563-8. PMID: 22147992 . The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Brünner-Kubath C, et al . Breast Cancer Res Treat. 2011 Sep,129(2):387-400. PMID: 21046231 .
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	EKB-569
Similar products	Pelitinib, EKB-569
Available
Molecular Weight	467, 92
Solubility	DMSO 10 mg/mL
Bioactivity information	Pelitinib (EKB-569) is an irreversible EGFR tyrosine kinase inhibitor with IC50 of 38.5 nM.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1904-200mg-safety-datasheet.pdf